Literature DB >> 18752030

Bio-enteric intragastric balloon in obese patients: a retrospective analysis of King Faisal Specialist Hospital experience.

Khalid Al Kahtani1, Mohammed Qaseem Khan, Ahmed Helmy, Hamad Al Ashgar, Mohammed Rezeig, Mohammed Al Quaiz, Ingvar Kagevi, Mohamed Al Sofayan, Mohammed Al Fadda.   

Abstract

BACKGROUND: Bio-enteric intragastric balloon (BIB) insertion is gaining popularity for weight reduction in obese patients. We evaluated the efficacy, tolerability, and safety of BIB in the treatment of obesity.
METHODS: A total of 173 Saudi obese patients [mean+/-SD age 34.5 +/- 11.6 years, 58 (33.5%) were men] who underwent BIB (InaMed Corporation, California, USA) insertion were followed up clinically, biochemically, and endoscopically for 6-12 months. The mean+/-SD baseline body weight, excess weight, and body mass index (BMI) were 123.5 +/- 39.6 and 68.9 +/- 40.0 kg and 46.7 +/- 14.1 kg/m(2), respectively. Associated dietary control, exercise, and medical treatment were used in 67 (38.7%), 60 (34.7%), and 3 (1.7%), respectively.
RESULTS: BIBs were safely and successfully inserted in 15.1 +/- 6.2 min, filled with 626.2 +/- 41.7 ml methylene blue solution, removed after a period of 189.7 +/- 68.3 days, within 14.1 +/- 6.3 min. BIB was not tolerated for 6 months in 33 (19.8%) patients. Body weight and BMI at 6 and 12 months postinsertion were significantly reduced to 112.5 +/- 35.7 kg and 43.1 +/- 13.1 kg/m(2), and 110.7 +/- 34.5 kg and 42.3 +/- 12.6 kg/m(2), respectively (p < 0.01 versus baseline by one-way ANOVA). Furthermore, the mean absolute weight loss and mean percentage excess weight reduction (EWR) at 6 and 12 months post-BIB insertion were 13.5 +/- 13.5 kg and 19.5 +/- 21.8, and 14 +/- 18.5 kg and 18.0 +/- 25.8, respectively. No mortality or major complications has occurred. EWR of >or=25% occurred in 24.1% and 30.1% of patients at 6 and 12 months postinsertion, respectively.
CONCLUSION: BIB is a safe, simple, and potentially efficient procedure that is well-tolerated by the majority of patients.

Entities:  

Mesh:

Year:  2008        PMID: 18752030     DOI: 10.1007/s11695-008-9654-0

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  43 in total

1.  Overweight and obesity worldwide now estimated to involve 1.7 billion people.

Authors:  Mervyn Deitel
Journal:  Obes Surg       Date:  2003-06       Impact factor: 4.129

2.  Tachyarrhythmia due to atrial fibrillation in an intragastric balloon carrier: coincidence or consequence?

Authors:  Francesco Puglisi; Palma Capuano; Nicola Veneziani; Pierluigi Lobascio; Angela D Di Franco; Giuseppe Lograno; Onofrio Caputi Iambrenghi
Journal:  Obes Surg       Date:  2005-05       Impact factor: 4.129

3.  Intragastric balloon in the treatment of super-morbid obesity. Double-blind, sham-controlled, crossover evaluation of 500-milliliter balloon.

Authors:  E M Mathus-Vliegen; G N Tytgat; E A Veldhuyzen-Offermans
Journal:  Gastroenterology       Date:  1990-08       Impact factor: 22.682

4.  Prevalence of overweight and obesity in diabetic and non-diabetic Saudis.

Authors:  M A el-Hazmi; A S Warsy
Journal:  East Mediterr Health J       Date:  2000 Mar-May       Impact factor: 1.628

5.  Is bariatric surgery necessary after intragastric balloon treatment?

Authors:  Luigi Angrisani; Michele Lorenzo; Vincenzo Borrelli; Monica Giuffré; Carmine Fonderico; Giuseppe Capece
Journal:  Obes Surg       Date:  2006-09       Impact factor: 4.129

6.  BioEnterics Intragastric Balloon: The Italian Experience with 2,515 Patients.

Authors:  A Genco; T Bruni; S B Doldi; P Forestieri; M Marino; L Busetto; C Giardiello; L Angrisani; L Pecchioli; P Stornelli; F Puglisi; M Alkilani; A Nigri; N Di Lorenzo; F Furbetta; A Cascardo; M Cipriano; M Lorenzo; N Basso
Journal:  Obes Surg       Date:  2005-09       Impact factor: 4.129

7.  Overweight and obesity in Saudi females of childbearing age.

Authors:  J S Al-Malki; M H Al-Jaser; A S Warsy
Journal:  Int J Obes Relat Metab Disord       Date:  2003-01

8.  High prevalence of overweight and obesity in Saudi Arabia.

Authors:  A R al-Nuaim; K al-Rubeaan; Y al-Mazrou; O al-Attas; N al-Daghari; T Khoja
Journal:  Int J Obes Relat Metab Disord       Date:  1996-06

9.  Preoperative weight loss by intragastric balloon in super-obese patients treated with laparoscopic gastric banding: a case-control study.

Authors:  Luca Busetto; Gianni Segato; Maurizio De Luca; Enzo Bortolozzi; Tommaso MacCari; Alessandro Magon; Eminé Meral Inelmen; Franco Favretti; Giuliano Enzi
Journal:  Obes Surg       Date:  2004-05       Impact factor: 4.129

10.  Intragastric balloons for morbid obesity: results, patient tolerance and balloon life span.

Authors:  E M Mathus-Vliegen; G N Tytgat
Journal:  Br J Surg       Date:  1990-01       Impact factor: 6.939

View more
  12 in total

Review 1.  Current status of intragastric balloon for obesity treatment.

Authors:  Seung Han Kim; Hoon Jai Chun; Hyuk Soon Choi; Eun Sun Kim; Bora Keum; Yoon Tae Jeen
Journal:  World J Gastroenterol       Date:  2016-06-28       Impact factor: 5.742

2.  One-year adjustable intragastric balloons: results in 73 consecutive patients in the U.K.

Authors:  J Brooks; E D Srivastava; E M H Mathus-Vliegen
Journal:  Obes Surg       Date:  2014-05       Impact factor: 4.129

3.  Efficacy of intragastric balloon for the management of obesity: experience from Kuwait.

Authors:  Salman Al-Sabah; Fahad Al-Ghareeb; Daliya AlMohammad Ali; Asmaa Al-Adwani
Journal:  Surg Endosc       Date:  2015-04-22       Impact factor: 4.584

4.  Response Rates with the Spatz3 Adjustable Balloon.

Authors:  Eduardo Usuy; Jeffrey Brooks
Journal:  Obes Surg       Date:  2018-05       Impact factor: 4.129

Review 5.  The Impact of Intragastric Balloons on Obesity-Related Co-Morbidities: A Systematic Review and Meta-Analysis.

Authors:  Violeta B Popov; Amy Ou; Allison R Schulman; Christopher C Thompson
Journal:  Am J Gastroenterol       Date:  2017-01-24       Impact factor: 10.864

6.  Randomized Prospective Clinical Study of Spatz3® Adjustable Intragastric Balloon Treatment with a Control Group: a Large-Scale Brazilian Experiment.

Authors:  Ricardo José Fittipaldi-Fernandez; Idiberto José Zotarelli-Filho; Cristina Fajardo Diestel; Márcia Regina Simas Torres Klein; Marcelo Falcão de Santana; João Henrique Felicio de Lima; Fernando Santos Silva Bastos; Newton Teixeira Dos Santos
Journal:  Obes Surg       Date:  2020-10-01       Impact factor: 4.129

7.  Intragastric Balloon Versus Endoscopic Sleeve Gastroplasty for the Treatment of Obesity: a Systematic Review and Meta-analysis.

Authors:  Shailendra Singh; Diogo Turiani Hourneaux de Moura; Ahmad Khan; Mohammad Bilal; Monica Chowdhry; Michele B Ryan; Ahmad Najdat Bazarbashi; Christopher C Thompson
Journal:  Obes Surg       Date:  2020-08       Impact factor: 4.129

8.  Adjustable intragastric balloons: a 12-month pilot trial in endoscopic weight loss management.

Authors:  Evzen Machytka; Pavel Klvana; Asher Kornbluth; Steven Peikin; Lisbeth E M Mathus-Vliegen; Christopher Gostout; Gontrand Lopez-Nava; Scott Shikora; Jeffrey Brooks
Journal:  Obes Surg       Date:  2011-10       Impact factor: 4.129

9.  Evaluation of the results of treatment of morbid obesity by the endoscopic intragastric balloon implantation method.

Authors:  Wojciech Żurawiński; Dariusz Sokołowski; Karolina Krupa-Kotara; Elżbieta Czech; Krystyn Sosada
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2017-03-30       Impact factor: 1.195

Review 10.  Prevalence, risk factors, and interventions for obesity in Saudi Arabia: A systematic review.

Authors:  Victoria Salem; Noara AlHusseini; Habeeb Ibrahim Abdul Razack; Anastasia Naoum; Omar T Sims; Saleh A Alqahtani
Journal:  Obes Rev       Date:  2022-03-26       Impact factor: 10.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.